Jyothi K Navya, Archana Jaka, Velpula Padma sujaya Velpula Padma sujaya, Pallavi Nayak Rupavath, R. R. C. Vaddadi
{"title":"covid-19期间疫苗药物警戒研究进展","authors":"Jyothi K Navya, Archana Jaka, Velpula Padma sujaya Velpula Padma sujaya, Pallavi Nayak Rupavath, R. R. C. Vaddadi","doi":"10.37022/jiaps.v6i2.226","DOIUrl":null,"url":null,"abstract":"Pharmacovigilance is important for collecting, detecting, monitoring adverse events which is the main objective. The adverse events reported should be assessed in order to know the casual relationship and avoid unnecessary effects on the recipient. Many people are vaccinating in a short period, so it is becoming much burden to the pharmacovigilance centers. The international society of pharmacovigilance (ISOP), the French national agency for medicines and health products safety (ANSM), and many others were in continuous collaboration and taking many initiatives to identify the safety and efficacy of vaccines and to provide answers to the raised questions respectively. Through pharmacovigilance, signals were detected, and many adverse events were identified. Pharmacovigilance of BioNTech/Pfizer-m-RNA, Moderna-mRNA vaccine, Covishield, Johnson and Johnson, Vaxzevria, Sputnik V, Convidecia are addressed. With BioNTech/Pfizer-m-RNA 12,249 ADRs, with Moderna-mRNA vaccine 577 ADRs, with Covishield 447 ADRs, with Johnson and Johnson 653 ADRs, with Vaxzevria 743 ADRs were reported. These vaccines resulted in immune thrombocytopenic purpura, cerebrovascular events, thrombosis, thrombocytopenia, facial paralysis, deaths, and many other reactions which may be fatal. But the events reported were less compared to the safety of the patients. All these events were maintained by the Uppsala monitoring center.","PeriodicalId":151037,"journal":{"name":"Journal of Innovations in Applied Pharmaceutical Science (JIAPS)","volume":"2015 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A review on vaccine pharmacovigilance during covid-19\",\"authors\":\"Jyothi K Navya, Archana Jaka, Velpula Padma sujaya Velpula Padma sujaya, Pallavi Nayak Rupavath, R. R. C. Vaddadi\",\"doi\":\"10.37022/jiaps.v6i2.226\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pharmacovigilance is important for collecting, detecting, monitoring adverse events which is the main objective. The adverse events reported should be assessed in order to know the casual relationship and avoid unnecessary effects on the recipient. Many people are vaccinating in a short period, so it is becoming much burden to the pharmacovigilance centers. The international society of pharmacovigilance (ISOP), the French national agency for medicines and health products safety (ANSM), and many others were in continuous collaboration and taking many initiatives to identify the safety and efficacy of vaccines and to provide answers to the raised questions respectively. Through pharmacovigilance, signals were detected, and many adverse events were identified. Pharmacovigilance of BioNTech/Pfizer-m-RNA, Moderna-mRNA vaccine, Covishield, Johnson and Johnson, Vaxzevria, Sputnik V, Convidecia are addressed. With BioNTech/Pfizer-m-RNA 12,249 ADRs, with Moderna-mRNA vaccine 577 ADRs, with Covishield 447 ADRs, with Johnson and Johnson 653 ADRs, with Vaxzevria 743 ADRs were reported. These vaccines resulted in immune thrombocytopenic purpura, cerebrovascular events, thrombosis, thrombocytopenia, facial paralysis, deaths, and many other reactions which may be fatal. But the events reported were less compared to the safety of the patients. All these events were maintained by the Uppsala monitoring center.\",\"PeriodicalId\":151037,\"journal\":{\"name\":\"Journal of Innovations in Applied Pharmaceutical Science (JIAPS)\",\"volume\":\"2015 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Innovations in Applied Pharmaceutical Science (JIAPS)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37022/jiaps.v6i2.226\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Innovations in Applied Pharmaceutical Science (JIAPS)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37022/jiaps.v6i2.226","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
药物警戒是收集、发现和监测不良事件的重要手段,也是药物警戒的主要目的。应对报告的不良事件进行评估,以了解其因果关系,避免对接受者产生不必要的影响。许多人在短时间内接种疫苗,这对药物警戒中心来说是很大的负担。国际药物警戒学会(ISOP)、法国国家药品和保健产品安全机构(ANSM)以及许多其他机构正在持续合作,并采取了许多举措,以确定疫苗的安全性和有效性,并分别对提出的问题提供答案。通过药物警戒,检测到信号,并确定了许多不良事件。讨论了BioNTech/Pfizer-m-RNA、Moderna-mRNA疫苗、Covishield、Johnson and Johnson、Vaxzevria、Sputnik V、Convidecia的药物警戒问题。BioNTech/Pfizer-m-RNA疫苗共报告12249例adr, Moderna-mRNA疫苗共报告577例adr, Covishield疫苗共报告447例adr, Johnson和Johnson疫苗共报告653例adr, Vaxzevria疫苗共报告743例adr。这些疫苗可导致免疫性血小板减少性紫癜、脑血管事件、血栓形成、血小板减少症、面瘫、死亡和许多其他可能致命的反应。但与患者的安全性相比,报道的事件较少。所有这些活动都由乌普萨拉监测中心维护。
A review on vaccine pharmacovigilance during covid-19
Pharmacovigilance is important for collecting, detecting, monitoring adverse events which is the main objective. The adverse events reported should be assessed in order to know the casual relationship and avoid unnecessary effects on the recipient. Many people are vaccinating in a short period, so it is becoming much burden to the pharmacovigilance centers. The international society of pharmacovigilance (ISOP), the French national agency for medicines and health products safety (ANSM), and many others were in continuous collaboration and taking many initiatives to identify the safety and efficacy of vaccines and to provide answers to the raised questions respectively. Through pharmacovigilance, signals were detected, and many adverse events were identified. Pharmacovigilance of BioNTech/Pfizer-m-RNA, Moderna-mRNA vaccine, Covishield, Johnson and Johnson, Vaxzevria, Sputnik V, Convidecia are addressed. With BioNTech/Pfizer-m-RNA 12,249 ADRs, with Moderna-mRNA vaccine 577 ADRs, with Covishield 447 ADRs, with Johnson and Johnson 653 ADRs, with Vaxzevria 743 ADRs were reported. These vaccines resulted in immune thrombocytopenic purpura, cerebrovascular events, thrombosis, thrombocytopenia, facial paralysis, deaths, and many other reactions which may be fatal. But the events reported were less compared to the safety of the patients. All these events were maintained by the Uppsala monitoring center.